Mechanisms of platelet-derived growth factor-induced arachidonic acid release in Swiss 3T3 fibroblasts: the role of a localized increase in free Ca2+ concentration beneath the plasma membrane and the activation of protein kinase C.
Stimulation of Swiss 3T3 fibroblasts with platelet-derived growth factor (PDGF) results in a transient increase in intracellular free Ca2+ concentration ([Ca2+]i) and a phospholipase A2 (PLA2)-dependent release of arachidonic acid (AA) of 500% over control values. In the absence of extracellular Ca2+, both the PDGF-induced transient increase in [Ca2+]i and AA release were markedly reduced. Buffering the increase in [Ca2+]i with EGTA, introduced into the cells in the form of EGTA acetoxymethylester (AM), abolished the PDGF-induced transient increase in [Ca2+]i, but potentiated the AA release by at least 2-fold compared to cells without EGTA. The EGTA potentiated PDGF-induced AA release was sensitive to extracellular Ca2+ and inhibited to various degrees by both receptor-mediated as well as voltage-operated Ca2+ channel blockers, suggesting that the release of AA may be tightly coupled to the influx of Ca2+. Activation of protein kinase C (PKC) by the phorbol ester, phorbol 12-myristate 13-acetate (TPA) had little effect in promoting AA release by itself. Down-regulation of PKC in Swiss 3T3 fibroblasts by chronic stimulation with 300 nM TPA for 24 h, markedly inhibited the PDGF-stimulated AA release in both the EGTA-loaded and control cells. In conditions where PDGF-induced AA release was inhibited or potentiated, the production of inositol phosphates was unaffected. Thus, PDGF-induced PLA2 dependent AA release in Swiss 3T3 fibroblast is regulated by both PKC-dependent and -independent mechanisms, and is activated by high concentrations of free Ca2+ in the microenvironment beneath the plasma membrane during Ca2+ influx via plasma-membrane Ca2+ channels, despite buffering by EGTA of [Ca2+]i in the bulk cytoplasm of the cell.
Chow
S C
SC
Department of Pharmacology, Mayo Clinic and Foundation, Rochester, MN.
Powis
G
G
D016475:3T3 Cells / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism*; D002021:Buffers; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002462:Cell Membrane / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology; D004789:Enzyme Activation; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism; D007295:Inositol Phosphates / Q000378:metabolism; D015759:Ionomycin / Q000494:pharmacology; D051379:Mice; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*; D011493:Protein Kinase C / Q000378:metabolism*
D002021:Buffers; D002121:Calcium Channel Blockers; D002614:Chelating Agents; D007295:Inositol Phosphates; D010982:Platelet-Derived Growth Factor; D016718:Arachidonic Acid; D015759:Ionomycin; D011493:Protein Kinase C; D002118:Calcium